![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Wisconsin, Madison Genentech |
Information provided by: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT00167791 |
This is a study of patients who have a high risk of kidney rejection before kidney transplant. The hypothesis is that treatment with a medication called rituximab will make it possible for them to receive a kidney transplant from a donor who previously did not present a good match.
Condition | Intervention |
End Stage Renal Disease |
Drug: rituximab |
MedlinePlus related topics: | Kidney Transplantation |
ChemIDplus related topics: | Rituximab |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Multicenter Trial Using Multi-Dose Rituximab as Induction and Desensitization Therapy for Patients on the Waiting List for Kidney Transplant With a Positive Donor Specific Crossmatch to a Living Donor |
Enrollment: | 0 |
Study Start Date: | July 2005 |
Study Completion Date: | March 2008 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Wisconsin | |||||
University of Wisconsin | |||||
Madison, Wisconsin, United States, 53792 |
University of Wisconsin, Madison |
Genentech |
Study Chair: | Yolanda T Becker, MD | University of Wisconsin, Madison |
Responsible Party: | University of WIsconsin ( Yolanda Becker, MD ) |
Study ID Numbers: | 2004-0265, RIST |
First Received: | September 9, 2005 |
Last Updated: | May 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00167791 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
![]() |